MedTrace Logo

Sildenafil Citrate Therapy for Oligohydramnios

NCT02372487 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2016-02-03

No results posted yet for this study

Summary

The aim of this randomized trial is to detect whether or not the use of Sildenafil citrate therapy will increase the amniotic fluid volume expressed in term of amniotic fluid index measured via ultrasound for fetuses of pregnancies complicated by oligohydramnios, and to compare the outcomes of Sildenafil-treated pregnancies with similar pregnancies that will remain Sildenafil-naïve.

Conditions

  • Pregnancy Complication

Interventions

DRUG

sildenafil citrate

sildenafil citrate 25 mg every 8 hours

DIETARY_SUPPLEMENT

fluid therapy

2 liters of fluid per day

Sponsors & Collaborators

  • Menoufia University

    collaborator OTHER

  • Al Hayat National Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Egypt
  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02372487 on ClinicalTrials.gov